| Basal cell carcinoma: treatment with imiquimod. | |
| | |
MedLine Citation:
|
PMID: 17472691 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Basal cell carcinoma (BCC) is the most common cutaneous malignancy. There are various approaches to its treatment, but imiquimod, the immune response modifier, offers a topical, noninvasive, nonsurgical therapeutic option. METHODS: We present our experience of the treatment of 96 patients with BCCs during the period March 2002 to February 2004 at the Dermatology Department, Hospital Clínico S. Cecilio, Granada, Spain. One hundred and forty-one tumors (nodular, superficial, and pearly/ulcerated clinical types) were treated with imiquimod. RESULTS: The clinical cure rate at 12 months was 80-85%. CONCLUSION: Our experience indicates that imiquimod is a reasonable option for the treatment of BCC. It is low cost, can be delivered via ambulatory care, and has tolerable side-effects. |
| | |
Authors:
|
M P Bukhardt Pérez; Ricardo Ruiz-Villaverde; M J Naranjo Díaz; J Blasco Melguizo; R Naranjo Sintes |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: International journal of dermatology Volume: 46 ISSN: 0011-9059 ISO Abbreviation: Int. J. Dermatol. Publication Date: 2007 May |
Date Detail:
|
Created Date: 2007-05-02 Completed Date: 2007-06-18 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0243704 Medline TA: Int J Dermatol Country: United States |
Other Details:
|
Languages: eng Pagination: 539-42 Citation Subset: IM |
Affiliation:
|
Dermatology Department, Hospital Clínico S. Cecilio, Granada, Spain. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adjuvants, Immunologic
/
adverse effects,
therapeutic use Adult Aged Aged, 80 and over Aminoquinolines / adverse effects, therapeutic use* Biopsy Carcinoma, Basal Cell / drug therapy* Erythema / chemically induced Female Humans Male Middle Aged Skin / drug effects, pathology Skin Neoplasms / drug therapy* Spain Time Factors Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Adjuvants, Immunologic; 0/Aminoquinolines; 99011-02-6/imiquimod |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Azelaic acid (15% gel) in the treatment of acne rosacea.
Next Document: Cleavage of neuronal synaptosomal-associated protein of 25 kDa by exogenous matrix metalloproteinase...